{"id":"https://openalex.org/W401190095","doi":"https://doi.org/10.1096/fasebj.29.1_supplement.lb181","title":"Unraveling binding interactions of serotonin 5\u2010HT 1B/1D receptor agonists on P\u2010glycoprotein: the gatekeeper of the brain","display_name":"Unraveling binding interactions of serotonin 5\u2010HT 1B/1D receptor agonists on P\u2010glycoprotein: the gatekeeper of the brain","publication_year":2015,"publication_date":"2015-04-01","ids":{"openalex":"https://openalex.org/W401190095","doi":"https://doi.org/10.1096/fasebj.29.1_supplement.lb181","mag":"401190095"},"language":"en","primary_location":{"id":"doi:10.1096/fasebj.29.1_supplement.lb181","doi":"https://doi.org/10.1096/fasebj.29.1_supplement.lb181","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fasebj.29.1_supplement.lb181","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5020510401","display_name":"Laura A. Wilt","orcid":"https://orcid.org/0000-0001-5723-1692","observed_orcids":["https://orcid.org/0000-0001-5723-1692"]},"institutions":[{"id":"https://openalex.org/I165733156","display_name":"University of Georgia","ror":"https://ror.org/00te3t702","country_code":"US","type":"education","lineage":["https://openalex.org/I165733156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Wilt","raw_affiliation_strings":["Pharmaceutical and Biomedical Sciences University of Georgia Athens GA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical and Biomedical Sciences University of Georgia Athens GA United States","institution_ids":["https://openalex.org/I165733156"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5050736930","display_name":"Arthur G. Roberts","orcid":"https://orcid.org/0000-0001-6045-458X","observed_orcids":["https://orcid.org/0000-0001-6045-458X"]},"institutions":[{"id":"https://openalex.org/I165733156","display_name":"University of Georgia","ror":"https://ror.org/00te3t702","country_code":"US","type":"education","lineage":["https://openalex.org/I165733156"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Arthur Roberts","raw_affiliation_strings":["Pharmaceutical and Biomedical Sciences University of Georgia Athens GA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pharmaceutical and Biomedical Sciences University of Georgia Athens GA United States","institution_ids":["https://openalex.org/I165733156"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I165733156"],"apc_list":{"value":3740,"currency":"USD","value_usd":3740},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.00617598,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"29","issue":"S1","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10570","display_name":"Drug Transport and Resistance Mechanisms","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11872","display_name":"Barrier Structure and Function Studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2808","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.0,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/p-glycoprotein","display_name":"P-glycoprotein","score":0.9950000047683716},{"id":"https://openalex.org/keywords/triptans","display_name":"triptans","score":0.7649999856948853},{"id":"https://openalex.org/keywords/blood-brain-barrier","display_name":"blood-brain barrier","score":0.8989999890327454},{"id":"https://openalex.org/keywords/drug-efflux","display_name":"drug efflux","score":0.8560000061988831},{"id":"https://openalex.org/keywords/eletriptan","display_name":"eletriptan","score":0.7570000290870667},{"id":"https://openalex.org/keywords/zolmitriptan","display_name":"zolmitriptan","score":1.0},{"id":"https://openalex.org/keywords/binding-interactions","display_name":"binding interactions","score":0.4790000021457672},{"id":"https://openalex.org/keywords/atpase-activity","display_name":"ATPase activity","score":0.8550000190734863},{"id":"https://openalex.org/keywords/tryptophan-fluorescence","display_name":"tryptophan fluorescence","score":0.8989999890327454},{"id":"https://openalex.org/keywords/cns-drug-development","display_name":"CNS drug development","score":0.4269999861717224},{"id":"https://openalex.org/keywords/verapamil","display_name":"verapamil","score":0.6620000004768372}],"concepts":[{"id":"https://openalex.org/C200082930","wikidata":"https://www.wikidata.org/wiki/Q22327148","display_name":"Efflux","level":2,"score":0.641722559928894},{"id":"https://openalex.org/C2778707650","wikidata":"https://www.wikidata.org/wiki/Q412902","display_name":"P-glycoprotein","level":4,"score":0.6172411441802979},{"id":"https://openalex.org/C44312359","wikidata":"https://www.wikidata.org/wiki/Q286958","display_name":"ATP-binding cassette transporter","level":4,"score":0.6050413250923157},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.5882632732391357},{"id":"https://openalex.org/C149011108","wikidata":"https://www.wikidata.org/wiki/Q652985","display_name":"Transporter","level":3,"score":0.5370954275131226},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.4802808463573456},{"id":"https://openalex.org/C2779085531","wikidata":"https://www.wikidata.org/wiki/Q218820","display_name":"Zolmitriptan","level":5,"score":0.4546826183795929},{"id":"https://openalex.org/C2778402981","wikidata":"https://www.wikidata.org/wiki/Q221694","display_name":"Blood\u2013brain barrier","level":3,"score":0.44702789187431335},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.4089284837245941},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.36491745710372925},{"id":"https://openalex.org/C12554922","wikidata":"https://www.wikidata.org/wiki/Q7100","display_name":"Biophysics","level":1,"score":0.3559987545013428},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.2882252335548401},{"id":"https://openalex.org/C529278444","wikidata":"https://www.wikidata.org/wiki/Q47273","display_name":"Central nervous system","level":2,"score":0.24187147617340088},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.22222211956977844},{"id":"https://openalex.org/C169760540","wikidata":"https://www.wikidata.org/wiki/Q207011","display_name":"Neuroscience","level":1,"score":0.1846296191215515},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.09111806750297546},{"id":"https://openalex.org/C133936738","wikidata":"https://www.wikidata.org/wiki/Q643839","display_name":"Multiple drug resistance","level":3,"score":0.08585965633392334},{"id":"https://openalex.org/C2778871607","wikidata":"https://www.wikidata.org/wiki/Q416978","display_name":"Sumatriptan","level":4,"score":0.0},{"id":"https://openalex.org/C501593827","wikidata":"https://www.wikidata.org/wiki/Q12187","display_name":"Antibiotics","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1096/fasebj.29.1_supplement.lb181","doi":"https://doi.org/10.1096/fasebj.29.1_supplement.lb181","is_oa":false,"landing_page_url":"https://doi.org/10.1096/fasebj.29.1_supplement.lb181","pdf_url":null,"source":{"id":"https://openalex.org/S25293849","display_name":"The FASEB Journal","issn_l":"0892-6638","issn":["0892-6638","1530-6860"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-2","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The FASEB Journal","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.9537000060081482,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"sustainable_development_goals_aurora":[{"score":0.7900000214576721,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2903943243","https://openalex.org/W2591662235","https://openalex.org/W2905986392","https://openalex.org/W3140824671","https://openalex.org/W4396660040","https://openalex.org/W4389021027","https://openalex.org/W2130914474","https://openalex.org/W4403892635","https://openalex.org/W2046826638","https://openalex.org/W2788275461"],"abstract_inverted_index":{"Lack":[0],"of":[1,15,24,42,54,80,114,134,149],"drug":[2,115,193],"penetration":[3],"through":[4],"the":[5,22,32,35,78,88,96,100,103,131,185,191,221],"blood\u2010brain":[6],"barrier":[7],"(BBB)":[8],"represents":[9],"a":[10,39,51],"formidable":[11],"hurdle":[12],"to":[13,120,165,200],"treatment":[14],"central":[16],"nervous":[17],"system":[18],"(CNS)":[19],"diseases":[20],"and":[21,37,44,66,83,117,139,159,169,183,188,196,207],"development":[23],"CNS":[25,55],"drugs.":[26],"The":[27,48],"transporter":[28],"P\u2010glycoprotein":[29,84],"(Pgp)":[30],"is":[31],"gatekeeper":[33],"at":[34],"BBB":[36],"effluxes":[38],"wide":[40],"range":[41],"chemically":[43],"structurally":[45],"diverse":[46],"neurotherapeutics.":[47],"triptans":[49],"represent":[50],"chemical":[52,81],"class":[53,90],"agonists":[56],"that":[57,77,106,123],"show":[58],"large":[59],"differences":[60,94],"in":[61,72,87,95,152,174,217],"their":[62,70],"Pgp":[63,151,182,216],"efflux":[64,140],"rates":[65,206],"transport":[67,85,110,158,189,205],"properties,":[68],"despite":[69],"similarities":[71],"molecular":[73,104,132],"structure.":[74],"We":[75,178],"hypothesize":[76],"variations":[79],"structure":[82],"rate":[86],"triptan":[89,135],"are":[91,107],"controlled":[92],"by":[93],"binding":[97,137,172],"location":[98],"on":[99,220],"transporter.":[101,222],"Identifying":[102],"features":[105],"critical":[108],"for":[109],"will":[111,118],"improve":[112],"predictions":[113],"disposition":[116],"lead":[119],"novel":[121],"neurotherapeutics":[122,213],"have":[124,179,201],"minimal":[125],"transport.":[126],"To":[127],"gain":[128],"insight":[129],"into":[130],"basis":[133],"transport,":[136],"interactions":[138,173],"ratios":[141],"were":[142,163,198],"characterized":[143,184],"within":[144],"our":[145,175],"biomimetic":[146,176],"model":[147],"consisting":[148],"reconstituted":[150,181],"artificial":[153],"membranes.":[154],"Specific":[155],"ATPase":[156,186,203],"activity,":[157,204],"intrinsic":[160,208],"tryptophan":[161,209],"fluorescence":[162],"used":[164],"investigate":[166],"eletriptan":[167],"(Relpax\u00ae)":[168],"zolmitriptan":[170,197],"(Zomig\u00ae)":[171],"model.":[177],"successfully":[180],"activity":[187],"with":[190,215],"probe":[192],"verapamil.":[194],"Eletriptan":[195],"identified":[199],"different":[202],"fluorescence,":[210],"suggesting":[211],"these":[212],"interact":[214],"distinct":[218],"regions":[219]},"counts_by_year":[],"updated_date":"2026-08-21T09:56:20.448147","created_date":"2016-06-24T00:00:00"}